Investigation of Hepatitis B virus DNA among HBsAg Positive Patients in Kabul, Afghanistan
PDF

Keywords

HBV
ELISA
PCR
Kabul
Replication

Categories

How to Cite

1.
Yousufi H, Zia Noori A, Rasekh H. Investigation of Hepatitis B virus DNA among HBsAg Positive Patients in Kabul, Afghanistan. Integr J Med Sci [Internet]. 2021 Feb. 17 [cited 2022 Jun. 30];8. Available from: https://www.mbmj.org/index.php/ijms/article/view/400

Abstract

Background: Hepatitis B virus (HBV) infections are one of the world's health problems that annually kill about 500,000 to 1,200,000 people. Investigation of HBV DNA in the person infected with HBV is a definitive indicator of activation and replication of HBV.Objectives: The aim of this study is to investigate the DNA of HBV in HBsAg positive patients and to study the risk factors for virus activation. Methods: This study was conducted on 106 HBsAg positive patients from January 2020 to July 2020 in Kabul. After informed consent, 3 to 5 milliliters of blood was collected for the HBV-DNA testing using the Real-time PCR method.Result: Out of 106 HbsAg positive patients, 74 (69.8%) were males and 32 (30.2%) females. The patients were aged between 11 and 65 years. Hepatitis B virus DNA was positive in 58 (54.7%) of the samples, 41 (70.7%) were male and 17 (29.3%) were female. The viral DNA load was in the range of 9.85 x 102 to 9.3 x 108 copies/ ml. Most of the patients were aged between 20 and 30 years. Conclusion: From 106 HbsAg positive patients, 23(39.7%) were in the age group of 20 – 30 years, and males were more infected than females. The majority of the patients were married and had an informal job with education below grade 12. No specific differences were found in the availability of HBV DNA between patients who received hepatitis B treatment before and those who did not.

 

 

https://doi.org/10.15342/ijms.2021.400
PDF

References

Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J gen virolog. 2000 Jan 1;81(1):67-74. https://doi.org/10.1099/0022-1317-81-1-67

Attaullah S, ur Rehman S, Khan S, Ali I, Ali S, Khan SN. Prevalence of Hepatitis B virus genotypes in HBsAg positiveindividuals of Afghanistan. Virol J. 2011 Jun 7;8:281. https://doi.org/10.1186/1743-422x-8-281

Belopolskaya M, Avrutin V, Firsov S, Yakovlev A. HBsAg level and hepatitis B viral load correlation with focus on pregnancy. Ann Gastroenterol. Jul-Sep 2015;28(3):379-384. [Accessed 2022 Apr 25]. Available from: https://www.scienceopen.com/document_file/5a829fc9-c779-4693-8d0c-6b75ac1b54fd/PubMedCentral/5a829fc9-c779-4693-8d0c-6b75ac1b54fd.pdf

Bati NS, Tekerekoglu MS, Duman Y. Investigation of HBV DNA in HBsAg positive patients. Medicine. 2017;6(4):706-9. https://dx.doi.org/10.5455/medscience.2017.06.8646

Abbas Z, Siddiqui AR. Management of hepatitis B in developing countries. World J Hepatol. 2011 Dec 27;3(12):292-9.https://doi.org/10.4254/wjh.v3.i12.292

Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. Can J Infect Dis Med Microbiol. 2005 Mar;16(2):65-72. https://doi.org/10.1155/2005/450574

Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM. 2012 Feb;105(2):109-13.https://doi.org/10.1093/qjmed/hcr270

Behzadi MA, Ziyaeyan M, Asaei S. Hepatitis B virus DNA level among the seropositive Afghan immigrants, southern Iran. Jundishapur J microbiol. 2014May;7(5). https://dx.doi.org/10.5812%2Fjjm.10127

Morgan M, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva gastroenterologica e dietologica. 2009 Mar;55(1):5-22.

European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012 Jul;57(1):167-85. https://doi.org/10.1016/j.jhep.2012.02.010

Yalcin K, Degertekin H, Alp MN, Tekes S, Satici O, Budak T. Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: clinical significance and correlation with serological markers. Turk J Gastroenterol. 2003 Sep;14(3):157-63.

Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995 Jan 1;13:S47-9. https://doi.org/10.1016/0264-410x(95)80050-n

Rasekh H, Naimi HM, Mousavi SH. Prevalence and Risk Factors of Hepatitis B, Hepatitis C and HIV Viruses Among People Who Use Drugs (PWUD) in Kabul, Health Care Facilities. Hepatitis Monthly. 2019 Jul 1;19(7).

Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC. HIV, hepatitis C, and hepatitis B infections and associated risk behavior in injection drug users, Kabul, Afghanistan. Emerg Infect Dis. 2007 Sep;13(9):1327-31. https://doi.org/10.3201/eid1309.070036

Ramezani A, Amirmoezi R, Volk JE, Aghakhani A, Zarinfar N, McFarland W, et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS care. 2014 Sep 2;26(9):1122-6. https://doi.org/10.1080/09540121.2014.882485

Mehmet D, Meliksah E, Serif Y, Gunay S, Tuncer O, Zeynep S. Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis. 2005 Feb;58(1):15-9.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Yousufi H et al.

Downloads

Download data is not yet available.